
    
      Assessment of the overall (OS); one year; two years and three years' survival rates; the
      disease free survival (DFS) and the tumor response rate in the patients undergoing Combined
      Ipsilateral Liver Lobe Devascularization and Alcohol Treatment (CILDAT) of the Large HCC.
      This is a prospective non randomized trial carried out at the Ribat University Hospital
      between May 2017 to April 2020.
    
  